Lipitor More Effective Than Simvastatin in Cutting Risk of Additional Heart Attacks in Patients Who Had a Recent Heart Attack, New Data Suggests

Geschrieben am 06-09-2006

New York (ots/PRNewswire) -

- Heart Disease Patients who Were at a Very High Risk for Having a
Second Heart Attack and Took Lipitor 80mg Had a 46 Percent Reduction
in the Risk of Experiencing Additional Heart Attacks Compared With
Patients Taking Simvastatin

- Investigator: 'These data suggest the benefit of intensive
treatment with Lipitor 80mg in very high-risk heart attack patients.'

Patients who had a recent heart attack and took Pfizer's
Lipitor(R) (atorvastatin calcium) 80mg dose experienced significantly
fewer heart attacks than patients taking simvastatin 20-40mg dose,
according to results of a new analysis presented today at the World
Congress of Cardiology in Barcelona, Spain.

"Patients who have experienced a recent heart attack are at
greater risk for experiencing life-threatening, recurrent events,"
said Dr. Terje Pedersen, head of the Centre for Preventive Medicine
at Ulleval University Hospital, Oslo, Norway, and the lead
investigator for IDEAL. "These data suggest the benefit of intensive
treatment with Lipitor 80mg in very high-risk heart attack patients.
Lipitor 80mg was also well-tolerated in these patients."

Patients who took Lipitor 80mg dose had a 46 percent reduction in
the risk of experiencing another heart attack, and a 34 percent
reduction in the risk of experiencing major coronary events, which
included heart attack, cardiac death and cardiac arrest, compared
with patients who took simvastatin 20-40mg dose. Lipitor 80mg also
significantly reduced the risk of death, stroke, unstable angina and
revascularization combined by 18 percent compared to simvastatin
20-40mg. The safety profiles were similar between the two groups.

This analysis was based on the IDEAL (Incremental Decrease in
Endpoints Through Aggressive Lipid Lowering) trial and was designed
and conducted after the trial ended. It represents the longest
follow-up of patients with a recent heart attack on statin therapy.

In IDEAL, 8,888 patients with coronary heart disease and
moderately elevated cholesterol levels were randomized to either
Lipitor 80mg or simvastatin 20-40mg and followed for an average of
4.8 years. These new findings are from an analysis of the 999
patients in IDEAL who experienced a heart attack less than two months
prior to entering the study.

"The often debilitating effects of a heart attack can place a
tremendous physical and emotional strain on patients and their
families," said Dr. Peter Ganz, associate professor of medicine,
Harvard Medical School. "These findings provide new and important
information about the potential benefit of intensive treatment with
Lipitor in the management of the risk of recurrent, potentially
life-threatening cardiac events."

Worldwide, heart disease is responsible for seven million deaths
annually. It is the single largest killer of Americans, causing one
out of every five deaths. An estimated 865,000 people suffer a new or
recurrent heart attack each year, according to data from the American
Heart Association.

The economic impact of heart attacks and strokes in the U.S. alone
totals nearly US$403 billion in medical care and lost productivity
annually. On an individual level, heart attacks and strokes are often
devastating experiences for the patient and his or her family.
Preventing a heart attack means avoiding hospitalization, a long
recovery period and weeks or months of lost work time associated with

"Lipitor is the only statin to show a significant benefit in these
very high risk heart disease patients, and has demonstrated greater
benefits than both simvastatin and pravastatin in clinical trials
studying these patients," said Dr. Joseph Feczko, Pfizer's chief
medical officer. "These findings add to the wealth of clinical data
that support the impressive efficacy and safety profile of Lipitor
across the dose range."

Since the introduction of Lipitor more than nine years ago, its
safety and effectiveness have been supported through an extensive
clinical trial program, Atorvastatin Landmarks, with more than 400
ongoing and completed trials involving more than 80,000 patients.
Lipitor is the most prescribed cholesterol-lowering therapy in the
world, with 121 million patient years of experience.

IDEAL was an investigator-led trial sponsored by Pfizer.

Important Information

Lipitor is a prescription drug. It is used in patients with
multiple risk factors for heart disease, such as family history, high
blood pressure, age, low HDL ("good" cholesterol), or smoking to
reduce the risk of heart attack and stroke. When diet and exercise
alone are not enough, Lipitor is used along with a low-fat diet and
exercise to lower cholesterol.

Lipitor is also used in patients with type 2 diabetes and at least
one other risk factor for heart disease, such as high blood pressure,
smoking or complications of diabetes, including eye disease and
protein in urine, to reduce the risk of heart attack and stroke.

Lipitor is not for everyone. It is not for those with liver
problems. And it is not for women who are nursing, pregnant or may
become pregnant.

If you take Lipitor, tell your doctor if you feel any new muscle
pain or weakness. This could be a sign of rare but serious muscle
side effects. Tell your doctor about all medications you take. This
may help avoid serious drug interactions. Your doctor should do blood
tests to check your liver function before and during treatment and
may adjust your dose. The most common side effects are gas,
constipation, stomach pain and heartburn. They tend to be mild and
often go away.

For more product information visit http://www.Lipitor.com or call

Web site: http://www.pfizer.com

ots Originaltext: Pfizer Inc.
Im Internet recherchierbar: http://www.presseportal.de

Vanessa Aristide, Pfizer Inc., +1-917-697-0487 cell, +1-212-733-3784
office ; Company News On-Call: Pfizer's press releases are available
through PR Newswire's Company News On-Call service on PRN's Web Site.
Visit http://www.prnewswire.com/comp/688250.html ; Photo: A free
corporate logo to accompany this story is available immediately via
Wieck Photo Database to any media with telephoto receiver or
electronic darkroom, PC or Macintosh, that can accept overhead
transmissions. To retrieve a logo, please call +1-972-392-0888.


Leider liegen uns zu diesem Artikel keine separaten Kontaktinformationen gespeichert vor.
Am Ende der Pressemitteilung finden Sie meist die Kontaktdaten des Verfassers.

Neu! Bewerten Sie unsere Artikel in der rechten Navigationsleiste und finden
Sie außerdem den meist aufgerufenen Artikel in dieser Rubrik.

Sie suche nach weiteren Pressenachrichten?
Mehr zu diesem Thema finden Sie auf folgender Übersichtsseite. Desweiteren finden Sie dort auch Nachrichten aus anderen Genres.


Weitere Informationen erhalten Sie per E-Mail unter der Adresse: info@bankkaufmann.com.

@-symbol Internet Media UG (haftungsbeschränkt)
Schulstr. 18
D-91245 Simmelsdorf

E-Mail: media(at)at-symbol.de


weitere Artikel:
  • Auf Ziel zu neuem Rekordjahr / Beste erste acht Monate der Marke Audi Ingolstadt (ots) - - Bis August: weltweit 601.500 Fahrzeuge übergeben (+8,6 Prozent) - Im August: weltweit 63.700 Fahrzeuge ausgeliefert (+7,7 Prozent) - Audi in China führende Premiummarke - Ziel für 2006: 50.000 Auslieferungen mehr als 2005 Mit weltweit 601.500 Auslieferungen an Kunden und einem Plus von 8,6 Prozent (2005: 553.991)* hat Audi in den ersten acht Monaten 2006 erneut einen Absatzrekord eingefahren. "Mit diesem Ergebnis fahren wir schwungvoll in das letzte Jahresdrittel und sind klar auf Kurs, 2006 den elften mehr...

  • Terma and Eurofighter sign Co-operation Agreement / The Eurofighter Consortium and Terma A/S have signed a Memorandum of Understanding, MoU, aiming to pursue areas of mutual interest Halbergsmoos/Lystrup (ots) - The background for the agreement is deliberations by the Danish government on which aircraft to select for the replacement of the F-16 during the coming years. The Eurofighter is among the three candidates for the replacement. A final decision is expected within the next 2-3 years. With this MoU, Terma and the Eurofighter Consortium are in a good position to pursue the industrial possibilities together in the event that the Eurofighter is selected. Terma, as the leading Defence and Aerospace Company in Denmark, mehr...

  • StepStone kooperiert mit absatzwirtschaft und SALESMASTERs / Strategische Partnerschaften für neuen Sales & Marketing Channel Düsseldorf (ots) - StepStone launcht seinen neuen Stellenmarkt für Vertriebs- und Marketing-Experten und gibt in diesem Rahmen die strategische Partnerschaft mit zwei namhaften Partnern bekannt. Die Kooperation mit absatzwirtschaft, dem auflagenstärksten monatlichen Fachmagazin für Marketing und Vertrieb in Deutschland, beinhaltet die Bereitstellung hochkarätiger journalistischer Beiträge für Entscheider in Marketing und Vertrieb. Im Rahmen der Kooperation sind darüber hinaus ab Mitte September alle Vertriebs- und Marketing-Jobs von StepStone mehr...

  • CoreMedia schließt Geschäftsjahr 2005/2006 mit Rekordergebnis ab Hamburg (ots) - CoreMedia, das globale Softwareunternehmen für das Geschäft mit digitalen Inhalten in konvergenten Märkten, hat das abgelaufene Geschäftsjahr 2005/2006 mit einem Rekordumsatz von 20,8 Mio. Euro abgeschlossen. Dies entspricht einer Umsatzsteigerung von über 40% gegenüber dem Vorjahr. CoreMedia konnte durch die Konzentration auf die Wachstumsbereiche Telekommunikation und Medien sowie marktnahe Innovationen, die globale Marktführerschaft im Zukunftsmarkt des Vertriebes digitaler Inhalte erreichen. Mit diesem Ergebnis mehr...

  • Contor Capital AG vernetzt Emittenten von Kapitalanlageprodukten mit Vertriebsspezialisten Lüdenscheid (ots) - - Strategische Beratung und operative Begleitung - Vernetzung, Coaching und Cross Network Marketing bei geschlossenen Fonds im Fokus Mit der Contor Capital AG mit Sitz in Hamburg, Lüdenscheid und München startet ein auf die strategisch-konzeptionelle Beratung von Finanzdienstleistern spezialisiertes Unternehmen. Contor Capital bietet Emittenten von Kapitalanlageprodukten umfassende Unterstützung bei der operativen Schulung und Steuerung des Produktvertriebs. "Die Vertriebskultur im Bereich Finanzprodukte mehr...

Mehr zu dem Thema Finanzen

Der meistgelesene Artikel zu dem Thema:

Century Casinos wurde in Russell 2000 Index aufgenommen

durchschnittliche Punktzahl: 0
Stimmen: 0

Bitte nehmen Sie sich einen Augenblick Zeit, diesen Artikel zu bewerten:

Sehr gut